Skip to main content

Renal Failure News (Page 5)

Related terms: Acute Kidney Failure, Acute Renal Failure, Chronic Renal Failure, Kidney Failure, CRF

Cardiovascular, Kidney, and Metabolic Syndrome Highly Prevalent in the U.S.

FRIDAY, May 10, 2024 – Cardiovascular, kidney, and metabolic (CKM) syndrome is highly prevalent in the United States, with more than 90 percent of adults meeting the criteria for stage 1 or higher,...

SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease

THURSDAY, May 2, 2024 – Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in patients with type 2 d...

FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease

VIENNA, VA. (PRWEB) JUNE 21, 2021 Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company’s New Drug Application for Soaanz, a o...

FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease

April 24, 2018 – TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved Jynarque (tolvaptan) as the first drug...

FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis

THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of...

Baxter Receives FDA Approval for Phoxillum Solution for Electrolyte Management During Continuous Renal Replacement Therapy

DEERFIELD, Ill., (January 20, 2015) - Baxter International Inc. (NYSE:BAX) today announced the United States Food and Drug Administration (FDA) has approved Phoxillum Renal Replacement Solutions...

FDA Medwatch Alert: Compounded Prescription Therapies By Pentec Health Inc.: Recall - Lack Of Sterility Assurance

ISSUE: Pentec Health, Inc. initiated a limited, voluntary recall of in-date nutritional prescriptions for renal patients due to lack of sterility assurance associated with one of its laminar flow...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Kidney Disease

Related drug support groups

Lasix, furosemide